- Home
- TRAK vs ENLV Comparison
TRAK vs ENLV Comparison
Compare TRAK & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRAK | ENLV |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.2M | 149.0M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TRAK | ENLV |
|---|---|---|
| Price | $8.56 | $4.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 53.6K | ★ 263.7K |
| Earning Date | 05-14-2026 | 05-29-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 20.69 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $21,007,076.00 | N/A |
| Revenue This Year | $6.61 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | $29.11 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $6.94 | $0.43 |
| 52 Week High | $18.47 | $7.64 |
Technical Indicators
Market Signals| Indicator | TRAK | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 57.97 |
| Support Level | $8.11 | $0.79 |
| Resistance Level | $9.09 | $7.64 |
| Average True Range (ATR) | 0.28 | 0.61 |
| MACD | -0.06 | -0.13 |
| Stochastic Oscillator | 51.81 | 50.92 |
Price Performance
Historical ComparisonAbout TRAK ReposiTrak Inc.
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.